The Daily Biotech Pulse: CHMP Backs AstraZeneca's Breast Cancer Therapies, Ipsen Buys Epizyme, FDA Holds For Nuvation Bio, Astellas Studies
The Daily Biotech Pulse: CHMP Backs AstraZeneca's Breast Cancer Therapies, Ipsen Buys Epizyme, FDA Holds For Nuvation Bio, Astellas Studies
每日生物技術脈搏：CHMP支持阿斯利康的乳腺癌療法，益普森收購Epizyme，美國食品藥品管理局持有Nuvation Bio，安斯泰來研究
Here's a roundup of top developments in the biotech space over the last 24 hours:
以下是過去 24 小時內生物技術領域的主要進展摘要：
Stocks In Focus
焦點股票
EMA's Advisory Committee Backs Approval For AstraZeneca's Targeted Breast Cancer Therapies
EMA的諮詢委員會支持批准阿斯利康的靶向乳腺癌療法
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended the approval of Enhertu (trastuzumab deruxtecan) and Lynparza (olaparib) for breast cancer settings.
歐洲藥品管理局人用藥品委員會（CHMP）已建議批准Enhertu（曲妥珠單抗 deruxtecan）和Lynparza（olaparib）用於乳腺癌治療。
Enhertu is being jointly developed and commercialized by AstraZeneca Plc (NASDAQ:AZN) and Daiichi Sankyo (OTC:DSNKY).
Enhertu 由以下機構共同開發和商業化阿斯利康有限公司（納斯達克股票代碼：AZN）和第一三共產株式會社（OTC: DSNKY）。
Lynparza is jointly developed and commercialized by AstraZeneca and Merck & Co Inc (NYSE:MRK).
Lynparza 由阿斯利康和默克公司（紐約證券交易所：MRK）。
Ipsen Buys Epizyme To Bolster Cancer Portfolio
益普森收購Epizyme以加強癌症投資組合
Ipsen...
I...
登入免費觀看全文
登入/註冊